Therapeutic Pembrolizumab antibody from the original Keytruda® commercial drug.
Product batch | Expiry date | Brand & Origin | Price | 1. Select quantity range | 2. Your quantity | |
---|---|---|---|---|---|---|
2018.07 |
Keytruda® DE |
264,00 €
/mg
|
Select quantity: Max: 20
Min: 2
Step: 2
|
Max: 20
Min: 2
Step: 2
|
||
2018.12 |
Keytruda® DE |
264,00 €
/mg
|
Select quantity: Max: 20
Min: 2
Step: 2
|
Max: 20
Min: 2
Step: 2
|
||
2019.03 |
Keytruda® DE |
264,00 €
/mg
|
Select quantity: Max: 20
Min: 2
Step: 2
|
Max: 20
Min: 2
Step: 2
|
||
2019.07 |
Keytruda® DE |
264,00 €
/mg
|
Select quantity: Max: 20
Min: 2
Step: 2
|
Max: 20
Min: 2
Step: 2
|
||
2025.10 |
Keytruda® DE |
198,00 €/mg
|
Max: 22
Min: 1
Step: 1
|
Evidentic’s analytical service includes a comprehensive array of methods to support the drug development process, including, for example, structure, aggregation, degree of isomerization and N-glycans identification of the active pharmaceutical ingredient (API).
Here you will find the product information for the reference product.
Drug name | Keytruda® |
INN | Pembrolizumab |
API type | Pembrolizumab is a humanized monoclonal anti-programmed cell death-1 (PD-1) antibody (IgG4/kappa isotype with a stabilizing sequence alteration in the Fc region) produced in Chinese hamster ovary cells by recombinant DNA technology |
Pharmacotherapeutic group | Antineoplastic agents, monoclonal antibodies |
ATC code | L01XC18 |
Target of antibody | PD-1; Synonyms: CD279, PD1, SLEB2, hPD-1, hPD-l, Ly101, Pdc1 |
General function | Pembrolizumab is a humanized monoclonal antibody which binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with ligands PD-L1 and PD-L2. |
Short description | |
Pharmacodynamic properties (Mechanism of action; Source EMA document) | The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Pembrolizumab potentiates T-cell responses, including anti-tumor responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumors or other cells in the tumor microenvironment. |
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document) | No formal pharmacokinetic drug interaction studies have been conducted with pembrolizumab. Since pembrolizumab is cleared from the circulation through catabolism, no metabolic drug-drug interactions are expected. The use of systemic corticosteroids or immunosuppressants before starting pembrolizumab should be avoided because of their potential interference with the pharmacodynamic activity and efficacy of pembrolizumab. However, systemic corticosteroids or other immunosuppressants can be used after starting pembrolizumab to treat immune-related adverse reactions. |
Original license holder | Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands |
Marketing authorisation numbers | EU/1/15/1024/002 |
Marketing authorisation holder | Merck Sharp & Dohme Limited Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom |
Name of the manufacturer of the biological active substance | MedImmune, LL C Frederick Manufacturing Center (FMC) 633/636/660 Research Court Frederick MD 21703-8619, USA Boehringer Ingelheim (BIB) Pharma GmbH & Co. KG Birkendorfer Straße 65 88397 Biberach an der Riss Germany |
Name and address of the manufacturer(s) responsible for batch release | Schering-Plough Labo NV Industriepark 30, Heist-op-den-Berg B-2220, Belgium |
Max shelf life | 24 months |
Storage conditions | 2°C – 8°C |
List of excipients | L-histidine L-histidine hydrochloride monohydrate Sucrose Polysorbate 80 |
Do you have any questions about the product, the ordering process or any other detail? Please contact us, we will reply within 24 hours.
At Evidentic, we deal with clinical-grade therapeutic molecules. Think of them as the building blocks for tomorrow’s groundbreaking treatments. These molecules are the active ingredients you’ll find in original drugs prescribed to patients, produced under the strictest quality and safety standards. They’ve also been therapeutically proven through rigorous clinical trials, meaning their effectiveness and safety for treating human diseases have been established. By offering researchers access to these essential tools, we’re fueling the fight for a healthier future.
Unlike some commercially available molecules, Evidentic’s clinical-grade therapeutics aren’t just research possibilities – they’re proven powerhouses! Derived from actual drugs used to treat human diseases, these molecules have already undergone rigorous testing and met the strictest safety and quality standards. This means researchers can focus their energy on groundbreaking discoveries, not questioning the reliability of their tools. With Evidentic, you get the confidence of knowing you’re working with the building blocks for real-world medical advancements.
If you struggle to source clinical-grade biologics you need for your research, Evidentic bridges the gap. We offer royalty-free research consumables (RUO-only) derived from original licensed drugs, giving you access to these critical research tools without the hassle.
But that’s not all. We understand the importance of batch variety in your research. That’s why we’ve built a comprehensive stock library, offering numerous batches of the same active pharmaceutical ingredient (API). This dedication to choice means you can find the exact batch that aligns with your specific research needs.
And because we’re constantly expanding our library, you can be sure we’re actively searching for new batches to add to your research arsenal. With Evidentic, unlock the power of readily available, high-quality research tools and accelerate your scientific breakthroughs.
Evidentic offers access to pharmaceuticals approved by the U.S. FDA (Food and Drug Administration) and/or the EMA (European Medicines Agency). This gives you access to a wider variety of molecules for your research, potentially shortening timelines and boosting the accuracy of your results. Compare EU and US molecules head-to-head, and accelerate your early drug development projects with access to these high-quality research tools. Contact us today to explore the possibilities!
Evidentic’s aliquots from approved pharnaceuticals can be used for analytical, in vitro research, typically executed in early drug development stage of drug discovery programs, like: